C5 and paroxysmal nocturnal hemoglobinuria: C5 inhibitors (C5i), eculizumab and ravulizumab, the current standard of care for PNH, inhibit terminal complement activation to prevent intravascular hemolysis and thrombosis, the disease processes that drive PNH morbidity and mortality [6, 9].